PTIX
Protagenic Therapeutics, Inc.NASDAQHealthcare$0.53-0.02%ClosedMarket Cap: $1.0M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-0.43
P/S
0.00
EV/EBITDA
-0.25
DCF Value
$-1.43
FCF Yield
-403.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
184.9%
ROA
-241.8%
ROIC
379.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $2.2M | $1.14 |
| FY 2025 | $0.00 | $-5.2M | $-3.45 |
| Q3 2025 | $0.00 | $-869.5K | $-0.47 |
| Q2 2025 | $0.00 | $-5.1M | $-1.37 |
Trading Activity
Insider Trades
View AllEVANS BARRETTdirector, 10 percent owner, officer: ex CEO
SellFri Oct 24
WRIGHT TIMOTHY Rdirector
SellMon Apr 01
Stein Robert Benjamindirector
SellFri Mar 29
Barrage Khalildirector
SellFri Mar 29
Buell Jenniferdirector
SellFri Mar 29
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.47
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.